Abstract | PURPOSE: METHODS: Eighty-five NDMM patients from multiple centers were randomly assigned to a high-dose (1.6 mg/m2) (group A) or a low-dose (1.3 mg/m2) (group B) bortezomib, administrated on days 1, 6, 11, and 16 subcutaneously in a 4-week cycle for nine cycles, combined with 40 mg dexamethasone on bortezomib days and cyclophosphamide 300 mg/m2 on days 1-3 intravenously. RESULTS: After four cycles, complete response (CR) or better in group A (43.6%) was higher than that in group B (12.8%) (P = 0.002). During induction, for patients with R-ISS stage III, the CR or better rate in group A was superior to that in group B (P = 0.01). Of patients < 65, the CR or better rate of group A was superior to that of group B (P = 0.004). Rapid onset of CR occurred in group A (P < 0.01). Meanwhile, rate of 3-4 diarrhea was higher in group A (P = 0.03), which caused higher rate of dose reduction for patients ≥ 65 (P = 0.041). No significant difference between the two groups in PFS and OS. CONCLUSIONS: The studied high-dose VCD as induction regimen had an improved CR rate, especially in patients < 65 or with R-ISS stage III, and is feasible for young and high-risk patients. Trial registration ClinicalTrials.gov: NCT02086942.
|
Authors | Feng Li, Fu-Sheng Yao, Xi-Jun Zhu, Wei-Ying Gu, Xiao-Hua Wang, Bing Chen, Dong-Ping Huang, Jia-Hua Ding, Tian-Qin Wu, Yan Zhu, Qian Zhao, Yu-Mei Tang, Ping Song, Xiao-Gang Zhou, Zhi-Ming An, Xing Guo, Xu-Li Wang, Long Zhong, Xiao-Bao Xie, Yong-Ping Zhai |
Journal | Journal of cancer research and clinical oncology
(J Cancer Res Clin Oncol)
Vol. 145
Issue 9
Pg. 2343-2355
(Sep 2019)
ISSN: 1432-1335 [Electronic] Germany |
PMID | 31280348
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Bortezomib
- Dexamethasone
- Cyclophosphamide
- Teniposide
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage)
- Bortezomib
(administration & dosage, adverse effects)
- Cyclophosphamide
(administration & dosage, adverse effects)
- Dexamethasone
(administration & dosage, adverse effects)
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Humans
- Injections, Subcutaneous
- Male
- Middle Aged
- Multiple Myeloma
(diagnosis, drug therapy)
- Teniposide
(administration & dosage)
- Treatment Outcome
|